文献速递糖尿病

循环促纤维化蛋白与2型糖尿病早期进行性肾功能下降风险

Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria.
PubMed 文献 · Diabetes Care · 2020-09-04

本研究基于Joslin肾脏研究队列,纳入eGFR≥60 mL/min/1.73 m2的2型糖尿病患者1181例(681例无白蛋白尿、500例有白蛋白尿),随访6-12年,发现基线WFDC2和MMP-7水平升高与早期进行性肾功能下降(eGFR年下降≥5 mL/min/1.73 m2)风险增加相关,且此关联独立于白蛋白尿状态。

要点

  • 基线WFDC2和MMP-7水平升高与早期进行性肾功能下降风险增加相关(P<0.0001)。
  • 纤维化指数每增加一个四分位数,肾功能下降风险OR为1.63(95%CI 1.30-2.04)。
  • 该关联在有和无白蛋白尿患者中均相似且具统计学显著性。

核心结论

  • 循环促纤维化蛋白升高与2型糖尿病早期进行性肾功能下降的发生相关,且独立于白蛋白尿状态。

研究设计与样本

  • Joslin肾脏研究队列中eGFR≥60 mL/min/1.73 m2的2型糖尿病患者1181例(681例无白蛋白尿,500例有白蛋白尿),随访6-12年。

主要发现

  • 随访期间152例发生快速早期进行性肾功能下降:正常白蛋白尿者中占6.9%,白蛋白尿者中占21%。
  • 在两组中,基线WFDC2(P<0.0001)和MMP-7(P<0.0001)水平越高,肾功能下降风险越高。
  • 调整相关临床特征和已知生物标志物后,纤维化指数(WFDC2与MMP-7组合)每增加一个四分位数,肾功能下降风险OR为1.63(95%CI 1.30-2.04)。
  • 该关联在有和无白蛋白尿患者中相似且具统计学显著性。

关键数值与推荐

  • 快速早期进行性肾功能下降定义为eGFR年下降≥5 mL/min/1.73 m2。
  • 基线中位eGFR为97 mL/min/1.73 m2,中位ACR为24 mg/g。

临床怎么用

  • 循环WFDC2和MMP-7可能作为2型糖尿病早期肾功能下降的纤维化相关生物标志物,尤其在不伴白蛋白尿的患者中值得关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The role of fibrosis in early progressive renal decline in type 2 diabetes is unknown. Circulating WFDC2 (WAP four-disulfide core domain protein 2) and matrix metalloproteinase 7 (MMP-7; Matrilysin) are postulated to be biomarkers of renal fibrosis. This study examined an association of circulating levels of these proteins with early progressive renal decline. RESEARCH DESIGN AND METHODS: Individuals with type 2 diabetes enrolled in the Joslin Kidney Study with an estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2 were monitored for 6-12 years to ascertain fast early progressive renal decline, defined as eGFR loss ≥5 mL/min/1.73 m2/year. RESULTS: A total of 1,181 individuals were studied: 681 without and 500 with albuminuria. Median eGFR and albumin-to-creatinine ratio (ACR) at baseline were 97 mL/min/1.73 m2 and 24 mg/g, respectively. During follow-up, 152 individuals experienced fast early progressive renal decline: 6.9% in those with normoalbuminuria and 21% with albuminuria. In both subgroups, the risk of renal decline increased with increasing baseline levels of WFDC2 (P < 0.0001) and MMP-7 (P < 0.0001). After adjustment for relevant clinical characteristics and known biomarkers, an increase by one quartile in the fibrosis index (combination of levels of WFDC2 and MMP-7) was associated with higher risk of renal decline (odds ratio 1.63; 95% CI 1.30-2.04). The association was similar and statistically significant among patients with and without albuminuria. CONCLUSIONS: Elevation of circulating profibrotic proteins is associated with the development of early progressive renal decline in type 2 diabetes. This association is independent from albuminuria status and points to the importance of the fibrotic process in the development of early renal decline.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Ihara K, Skupien J, Kobayashi H, et al. Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria. Diabetes Care. 2020. PMID: 32887710. doi:10.2337/dc20-0630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。